Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108297 · ClinicalTrials.gov registry record · Phase 1
Lithium Long COVID Dose-finding Study
A Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06108297: Completed Phase 1 study, sponsored by State University of New York at Buffalo.
NCT06108297 is a Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06108297, a Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.
Primary Outcome
7-item scale. Score range 1-49 with higher values signifying worse outcome
Interventions
- DIETARY_SUPPLEMENT Lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 1 |
What the finished NCT06108297 record still lists
NCT06108297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Lithium is the first listed.
NCT06108297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06108297 about?
NCT06108297 is a clinical study titled "Lithium Long COVID Dose-finding Study". This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.
What is the current status of trial NCT06108297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-10-12. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT06108297?
The interventions under investigation include: Lithium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06108297?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06108297's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI